Mineralocorticoid receptor antagonists such as eplerenone and spironolactone are increasingly being administered to patients with resistant hypertension,210 and they may be a useful option in the management of cancer therapy-associated hypertension that is unresponsive to conventional therapy. This evidence concerns the gene NR3C2 and hypertensive disorder.